The Indian government said on Sunday the ban would apply to offset rising domestic demand.
“The export of injectable remdesivir and remdesivir Active Pharmaceutical Ingredients (API) will be banned until Covid-19 The situation in the country is improving, “the government said in a statement.
There is currently an increase in coronavirus cases in India. As of April 11, there are 110,008 new active Covid cases. As a result, there has been a sudden surge in demand for remdesivir, the drug used to treat Covid patients. People form long queues stretching 2 kilometers to get the drug.
Read: US Approves Gilead’s Remdesivir Drug For Covid-19 Patients
India has suspended vaccine exports in March to match rising domestic demand with international orders. The export ban means poorer nations will likely have to wait a few months before receiving their first shots.
Remdesivir is considered an important antiviral drug in the fight against Covid-19, especially in adult patients with serious complications. < / p>
Shortening recovery time
In November last year, the Kenyan government gave hospitals permission to use the antiviral drugs that are supposed to shorten the recovery time from Covid. 19 patients.
The Pharmacy and Poisons Board (PPB) has given several hospitals in the country a Compassionate Use Authorization (CUA) for remdesivir after studies in the United States showed it was possible is reducing the recovery time of Covid-19 patients.
As a result, Kenya approved Remdesivir, a drug originally developed to treat Ebola. It is one of the two drugs that can work against the virus. The other drug is dexamethasone.
Although it appears to be in high demand in 50 countries around the world, the Pharmacy Board announced on Sunday that it had stopped licensing the drug has drug in the country after the World Health Organization (WHO) issued a conditional recommendation against use in hospitalized patients regardless of the severity of the disease in November, as there is currently no evidence that remdesivir improves survival and other outcomes in these patients.
Read: New questions about the effectiveness of remdesivir in the treatment of Covid-19
“said the agency’s guideline development group.
On the recommendation of the deputy Director of Product Evaluation and Registration of the Pharmacy and Poisons Board, Dr Peter Mbwiri Ikamati said the drug had not received an emergency approval so it shouldn’t be used in Kenya.
“We shouldn’t be using it, because PPB did not authorize it, “Dr. Ikamati told Nation.
Dr. Ikamati added that the Board currently only approves drugs that have been approved for use by the World Health Organization .
During the publication of the revised guidelines, the WHO added, the expert group highlighted these clinical trial data showing that the drug did not increase patient survival.
It was said: “The panel interpretie judge the evidence so that it does not prove that remdesivir is ineffective; Rather, based on the data currently available, there is no evidence that it improves outcomes that are important to the patient. “
Read: The experimental viral drug remdesivir fails in a human trial.
As of July 2020 Kenya was among 126 low- and low-middle-income countries identified by Gilead Sciences to obtain generic versions of the drug. It is made by five companies licensed to manufacture for developing countries.
The drug This was tested for Ebola but did not work as expected and is for Gilead patented. This means that no other company in rich countries can manufacture it.
However, a non-exclusive voluntary licensing agreement will allow pharmaceutical manufacturers in India and Pakistan to manufacture and sell the treatment at significantly lower costs, ” Gilead said in a statement.
Under the terms of the agreements, companies have the right to technology transfer from Gilead so they can manufacture Get the drug quickly.
Generics are copies of branded drugs that have the same dosage, intended use, effects, side effects, administration routine, risks, safety and strength as the original.